Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma.

Manish Sharma, MD, Peter Thall, PhD, Xuemei Wang, PhD, Chitra Hosing, MD, Floralyn L Mendoza, MD, Eric Han, MD, Michael Wang, MD, Donna Weber, MD, Jatin Shah, MD, Amin Alousi, MD, Paolo Anderlini, MD, Partow Kebriaei, MD, Issa F Khouri, MD, Uday Popat, MD, Marcos de Lima, MD, Richard E Champlin, MD, Sergio Giralt, MD, Muzaffar Qazilbash, MD

Blood (2009) 114 (22): 2309.

https://doi.org/10.1182/blood.V114.22.2309.2309

Published: 2009

Journal Articles

Identifying Relapsed AML Patients Most Likely To Benefit from Allogeneic Stem Cell Transplant: A Statistical Subgroup Analysis.

Paul M. Armistead, MD, PhD, Marcos de Lima, MD, Sherry Pierce, RN, Wei Qiao, PhD, Xuemei Wang, PhD, Peter Thall, PhD, Sergio Giralt, MD, Richard Champlin, MD, Elihu Estey, MD

Blood (2007) 110 (11): 329.

https://doi.org/10.1182/blood.V110.11.329.329

Published: 2007

Journal Articles

Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): A Dose and Schedule Finding Study.

Andres O. Soriano, MD, Richard Champlin, MD, Gloria McCormick, Sergio Giralt, MD, Peter Thall, PhD, Krishna Komanduri, MD, Muzaffar Qazilbash, MD, Guillermo Garcia-Manero, MD, Marcos De Lima, MD

Blood (2006) 108 (11): 3668.

https://doi.org/10.1182/blood.V108.11.3668.3668

Published: 2006

Journal Articles

Phase II/III Randomized Study Comparing Two Different Tacrolimus Blood Levels for the Prevention of Graft-Versus-Host Disease (GVHD).

Daniel R. Couriel, MD, Peter Thall, PhD, Kerry Mickler, RN, Marcos De Lima, MD, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD, Chitra Hosing, MD, Issa Khouri, MD, Partow Kebriaei, MD, Yvonne Hsu, MD, Rima Saliba, MD, Cindy Ippoliti, PharmD, Richard Champlin, MD

Blood (2005) 106 (11): 142.

https://doi.org/10.1182/blood.V106.11.142.142

Published: 2005

Journal Articles

Plausibility of Delaying Induction Therapy in Untreated AML.

Elihu H. Estey, MD, X.-M. Wang, MS, Peter Thall, PhD, Sherry Pierce, BSN, Charles Koller, MD, Stefan Faderl, MD, Srdan Verstovsek, MD, Jorge Cortes, MD, Guillermo Garcia-Manero, MD, Hagop Kantarjian, MD

Blood (2004) 104 (11): 879.

https://doi.org/10.1182/blood.V104.11.879.879

Published: 2004

NARROW

A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma.

Identifying Relapsed AML Patients Most Likely To Benefit from Allogeneic Stem Cell Transplant: A Statistical Subgroup Analysis.

Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): A Dose and Schedule Finding Study.

Phase II/III Randomized Study Comparing Two Different Tacrolimus Blood Levels for the Prevention of Graft-Versus-Host Disease (GVHD).

Plausibility of Delaying Induction Therapy in Untreated AML.

Email alerts

ASH Publications

American Society of Hematology

A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma.

Identifying Relapsed AML Patients Most Likely To Benefit from Allogeneic Stem Cell Transplant: A Statistical Subgroup Analysis.

Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): A Dose and Schedule Finding Study.

Phase II/III Randomized Study Comparing Two Different Tacrolimus Blood Levels for the Prevention of Graft-Versus-Host Disease (GVHD).

Plausibility of Delaying Induction Therapy in Untreated AML.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only